Helius Medical Technologies, a neurotech company specializing in delivering a new therapeutic neuromodulation approach for patients with balance and gait deficits, announced results for the quarter and fiscal year ended December 31, 2022. The company demonstrated sequential quarterly revenue growth, and several programs were launched to increase access to PoNS Therapy. Dane Andreeff, the CEO of Helius, stated that PoNS is a breakthrough technology with a tremendous opportunity to help patients suffering from balance and gait impairment. The company expects 2023 revenues to exceed the prior year's level, and quarterly fluctuations might occur as refinements are made to the U.S. commercial roll-out of PoNS. The company believes broad third-party payer reimbursement is required to achieve its full revenue potential. The PoNS is a Portable Neuromodulation Stimulator device that delivers electrical stimulation to the tongue's surface to improve balance and gait. Helius does not bear any debt and had $14.11 million in cash and cash equivalents at December 31, 2022. The reader should bear in mind that certain statements constitute forward-looking statements and involve risks and uncertainties that could differ from actual results.